EXEL
The analyst note got a little less bubbly
Exelixis just lost some of its shine after Wall Street Zen downgraded the stock from strong-buy to buy. That’s not a full-on faceplant, but it does mean the enthusiasm dial got turned down a notch.
Why you should care
For a biotech name like Exelixis, sentiment matters. When analysts start sounding less caffeinated, investors tend to notice — especially when the company’s latest earnings already gave people a mixed bag to chew on.
Here’s the backdrop:
- Exelixis posted $0.94 in EPS, topping expectations of $0.74
- Revenue came in at $598.66 million, missing the $609.17 million forecast
- Sales still grew 5.6% year over year, so it wasn’t a disaster, just not a clean victory lap
And then there’s the stockholder tea
The article also flagged an insider sale: SVP Brenda Hefti sold 18,669 shares at $44.01 each, for roughly $821,623. One sale doesn’t make a thesis, but it’s the kind of detail that can make investors squint a little harder at the chart.
Big picture
Exelixis is still profitable and still growing, but this isn’t the kind of headline that makes traders hit the buy button with both feet. The stock can still work here — just maybe with less swagger and more spreadsheet energy.